Welcome to our dedicated page for AGIOS PHARMACEUTICALS SEC filings (Ticker: AGIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Agios Pharmaceuticals, Inc. filings document the regulatory record of a Delaware, Nasdaq-listed commercial-stage biopharmaceutical company focused on rare diseases and hematology. Its 8-K reports furnish operating results, product revenue updates for PYRUKYND® and AQVESME™, business highlights, investor presentations, and Regulation FD disclosures tied to mitapivat commercialization, clinical programs, and regulatory interactions.
Proxy and current-report filings cover annual-meeting proposals, director elections, board-class structure, committee assignments, stockholder voting matters, and compensatory arrangements for directors. Other disclosures address board appointments, pharmacovigilance communications involving PYRUKYND, exhibit filings, and Inline XBRL cover-page data.
Agios Pharmaceuticals reported first-quarter 2026 product revenue of $20.7 million, up from $8.7 million a year earlier, driven by PYRUKYND® and the late-2025 U.S. launch of AQVESME™ for thalassemia and initial rest-of-world sales.
The company posted a net loss of $99.1 million, or $1.69 per share, as it increased research and development spending to $81.1 million and selling, general and administrative costs to $48.3 million to support its expanding rare-disease portfolio and commercialization.
Agios ended March 31, 2026 with $1.0 billion in cash, cash equivalents and marketable securities, and expects this to fund operations for at least 12 months while advancing mitapivat in thalassemia and sickle cell disease, tebapivat in lower-risk MDS and SCD, AG-181 in PKU, and AG-236 in polycythemia vera.
Agios Pharmaceuticals reported first quarter 2026 results showing rapid growth in its rare disease franchise but continued investment-driven losses. Mitapivat (PYRUKYND® and AQVESME™) generated worldwide net revenues of $20.7 million, up from $8.7 million in the first quarter of 2025, supported by a strong U.S. launch of AQVESME in thalassemia with 242 prescriptions written as of March 31, 2026.
Net loss for the quarter was $99.1 million compared to $89.3 million a year earlier, reflecting higher R&D spending of $81.1 million and SG&A expenses of $48.3 million. Cash, cash equivalents and marketable securities totaled $1.0 billion as of March 31, 2026. The company plans to submit a supplemental NDA for mitapivat in sickle cell disease in the second quarter of 2026 and expects Phase 2 tebapivat readouts in myelodysplastic syndromes and sickle cell disease later in 2026.
Agios Pharmaceuticals is holding its 2026 Annual Meeting of Stockholders as a fully virtual webcast on June 18, 2026 at 9:00 a.m. Eastern Time. Stockholders of record at the close of business on April 21, 2026, when 59,471,609 common shares were outstanding, may vote.
Items up for vote include electing three Class I directors to terms ending in 2029, an advisory say‑on‑pay vote on executive compensation, approval of an amendment to the 2023 Stock Incentive Plan to increase available shares, and ratification of PricewaterhouseCoopers LLP as independent auditor for 2026. A majority of outstanding shares, about 29,735,805, is needed for a quorum. The company uses internet “notice and access” and emphasizes ESG initiatives, flexible work culture and extensive governance structures.
Agios Pharmaceuticals Chief Legal Officer James William Burns exercised 8,500 performance share units into 8,500 shares of common stock. The PSUs vested when a specified regulatory milestone was determined to be met on April 2, 2026. On the same date, 3,280 shares were sold at $34.71 per share to cover tax withholding obligations under durable automatic sale instructions consistent with Rule 10b5-1(c). Following these transactions, Burns directly holds 49,306 shares of Agios common stock.
AGIOS PHARMACEUTICALS, INC. Chief Medical Officer Sarah Gheuens exercised performance share units that converted into 8,500 shares of common stock on April 2, 2026 after a specified regulatory milestone was achieved.
Each performance share unit represented a contingent right to receive one share of common stock, and the grant was originally made on March 1, 2024. Following this vesting and exercise, Gheuens sold 2,940 shares of common stock at $34.71 per share to cover tax withholding obligations under durable automatic sale instructions consistent with Rule 10b5-1(c). After these transactions, she directly owns 80,277 common shares, which include 311 shares purchased through the company’s employee stock purchase plan.
Agios Pharmaceuticals' Chief Financial Officer Cecilia Jones exercised performance share units and sold shares primarily to cover taxes. She converted 8,500 performance share units into 8,500 shares of common stock after a specified regulatory milestone was determined to have been met on April 2, 2026. On the same date, 3,141 shares were sold at $34.71 per share to satisfy tax withholding obligations under durable automatic sale instructions included in her March 1, 2024 performance share unit agreement, which is structured to be consistent with the Rule 10b5-1(c) affirmative defense. After these transactions, she directly held 54,998 shares of common stock, including 311 shares acquired through the company’s employee stock purchase plan.
Agios Pharmaceuticals Chief Commercial Officer Tsveta Milanova reported a vesting and tax-related sale of shares. On April 2, 2026, 8,500 performance share units were exercised into 8,500 shares of common stock at $0.00 per share, reflecting the vesting of performance-based equity compensation tied to a specified regulatory milestone.
On the same date, 3,262 shares of common stock were sold at $34.71 per share to cover tax withholding obligations, executed under durable automatic sale instructions consistent with Rule 10b5-1(c). After these transactions, Milanova directly owned 46,829 shares of Agios common stock.
Agios Pharmaceuticals executive Krishnan Viswanadhan reported an exercise-and-sell transaction tied to performance share units (PSUs). On April 2, 2026, 8,100 PSUs converted into 8,100 shares of common stock at $0.00 per share when a specified regulatory milestone was achieved.
On the same date, 2,959 shares were sold at $34.71 per share to cover tax withholding obligations under durable automatic sale instructions consistent with Rule 10b5-1(c). After these transactions, he held 10,282 shares of Agios common stock directly.
Agios Pharmaceuticals Chief Executive Officer Brian Goff reported vesting and settlement of performance share units tied to regulatory milestones, resulting in the delivery of 39,028 shares of common stock. On the same date, 19,068 shares were sold at $34.71 per share to cover tax withholding obligations under durable automatic sale instructions consistent with Rule 10b5-1(c). Following these compensation-related transactions, he holds 184,508 common shares directly.